Description General description A cell-permeable quinolinyl-thiourea compound that acts a potent, ATP-competitive, and reversible inhibitor of PDGFR (IC50 = 4 and 7.6 nM in ligand-induced cellular PDGFR phosphorylation and in in vitro kinase activity, respectively). Inhibits c-kit receptor only at much higher concentrations (IC50 = 434 and 234 nM in receptor phosphorylation and kinase activity, respectively). Shown to potently inhibit neointima formation in a rat carotid artery balloon injury model in vivo (30 mg/kg, p.o.). Packaging 1 mg in Plastic Bag(s) Biochem/physiol Actions Cell permeable: yes Primary Target PDGFR Product competes with ATP. Reversible: yes Target IC50: 4 and 7.6 nM in ligand-induced cellular PDGFR phosphorylation and in in vitro kinase activity, respectively Packaging Packaged under inert gas Warning Toxicity: Toxic (F) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges. Getachew, R., et al. 2009. Eur. J. Pharmacol.<→i> In press. Nishioka, C., et al. 2008. Blood111, 5086. Furuta, T., et al. 2006. J. Med. Chem.49, 2186.